Think from memory the final two payments to Boneyard are due in March and September, so cash will be used to clear that for now.
The discount rate used to value biological assets is 20%, so means NTA makes a good rough bottom line for valuing (assuming most investors here like a generous margin for error in purchase price when dealing with micro-caps)
Ann: 31 December 2021 Interim Financial Report, page-21
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.003(3.00%) |
Mkt cap ! $42.21M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.7¢ | $153.4K | 1.522M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 259453 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 61411 | 2 |
View Market Depth
| Last trade - 15.36pm 30/07/2024 (20 minute delay) ? |
| ATP (ASX) Chart |